Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

Benjamin Rolles, Jan Philipp Bewersdorf, Tariq Kewan, Ondrej Blaha, Jessica Stempel, Luca Lanino, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Eunice Wang, Maria Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Talha Badar, Jaclynn Campos, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop Enjeti, Kamal Alrabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Matteo Della Porta, Rami Komrokji, Amer Zeidan, Maximilian Stahl

Blood (2025) 146 (Supplement 1): 3865.

https://doi.org/10.1182/blood-2025-3865

Published: 2025

Journal Articles

Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database

Tariq Kewan, Jan Philipp Bewersdorf, Luca Lanino, Ondrej Blaha, Jessica Stempel, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Benjamin Rolles, Eunice Wang, Amyah Harris, Maria Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Talha Badar, Jaclynn Campos, Torsten Haferlach, Jaroslaw Maciejewski, Anoop Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Rami Komrokji, Maximilian Stahl, Matteo Della Porta, David Sallman, Amer Zeidan

Blood (2025) 146 (Supplement 1): 3863.

https://doi.org/10.1182/blood-2025-3863

Published: 2025

Journal Articles

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

Ted Getz, Kelly Pugh, Andrew Brunner, Jan Philipp Bewersdorf, Amy DeZern, Tariq Kewan, Uma Borate, Uwe Platzbecker, Mikkael Sekeres, Andrew Wei, Shahram Kordasti, Rena Buckstein, Gail Roboz, Michael Savona, Sanam Loghavi, Robert Hasserjian, Pierre Fenaux, David Sallman, Christopher Hourigan, Matteo Della Porta, Stephen Nimer, Richard Little, Valeria Santini, Fabio Efficace, Justin Taylor, Olatoyosi Odenike, Tae Kon Kim, Stephanie Halene, Rami Komrokji, Elizabeth Griffiths, Peter Greenberg, Mina Xu, Zhuoer Xie, Rafael Bejar, Guillermo Sanz, Mrinal Patnaik, Maria E. Figueroa, Hetty Carraway, Omar Abdel-Wahab, Daniel Starczynowski, Eric Padron, Jacqueline Boultwood, Steven Gore, Naval Daver, Jane Churpek, Ravi Majeti, John Bennett, Alan List, Adrian Mosquera Orgueira, Klaus Metzeler, Francesc Sole, Lisa Pleyer, Arjan Van de Loosdrecht, Thomas Cluzeau, David Steensma, Ghulam Mufti, Lionel Ades, Luca Lanino, Yazan Madanat, Anne Sophie Kubasch, Marie Sebert, R. Coleman Lindsley, Katharina S. Götze, Carmelo Gurnari, Yasushi Miyazaki, Aref Al-Kali, Abdulraheem Yacoub, Bing Li, Ioannis Kotsianidis, Maximilian Stahl, Amer Zeidan

Blood (2025) 146 (Supplement 1): 3852.

https://doi.org/10.1182/blood-2025-3852

Published: 2025

Journal Articles

Establishing contemporary benchmarks for Acute Myeloid Leukemia outcomes and measurable residual disease: Real-world data utilization from the ELN-david MRD international working group

Blood (2025) 146 (Supplement 1): 5183.

https://doi.org/10.1182/blood-2025-5183

Published: 2025

Journal Articles

Disease characteristics and outcomes of acute lymphoblastic leukemia (ALL) in adults with central nervous system (CNS) involvement

Michal Bar-Natan, Sarra Yekta, Justin Kaner, Jonathan Canaani, Pinkal Desai, Ellen Ritchie, Michael Samuel, Hannah Levavi, Eshani Pareek, Debra D'Angelo, Gail Roboz

Blood (2025) 146 (Supplement 1): 1557.

https://doi.org/10.1182/blood-2025-1557

Published: 2025

Journal Articles

Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacitidine (Pbo+Aza) in patients with treatment-naïve, intermediate and higher-risk Myelodysplastic Syndromes (HR MDS)

Blood (2025) 146 (Supplement 1): 235.

https://doi.org/10.1182/blood-2025-235

Published: 2025

Journal Articles

Pharmacokinetics and cardiac impact of arsenic trioxide (ATO) oral solution (SDK001) under fasting, fed, and calcium carbonate co-administration conditions compared with intravenous ATO in patients with acute promyelocytic leukemia

Harinder Gill, Farhad Ravandi, Jessica Altman, Gail Roboz, Tony Wu, Garret Leung, Danelle James, Stephane Berthier, Yok-Lam Kwong

Blood (2025) 146 (Supplement 1): 1506.

https://doi.org/10.1182/blood-2025-1506

Published: 2025

Journal Articles

A randomized, multicenter trial of shorter durations of hypomethylating agents in lower-risk Myelodysplastic Syndromes

Blood (2025) 146 (Supplement 1): 487.

https://doi.org/10.1182/blood-2025-487

Published: 2025

Journal Articles

Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: Phase 1b results from KOMET-007

Blood (2025) 146 (Supplement 1): 766.

https://doi.org/10.1182/blood-2025-766

Published: 2025

Journal Articles

Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007

Blood (2025) 146 (Supplement 1): 764.

https://doi.org/10.1182/blood-2025-764

Published: 2025

Journal Articles

ONC001: A first-in-class ADC targeting CD64 for the treatment of monocytic leukemia developed through patient-guided target and payload selection

Blood (2025) 146 (Supplement 1): 324.

https://doi.org/10.1182/blood-2025-324

Published: 2025

Journal Articles

Redefining eIF4E's function in Acute Myeloid Leukemia: Implications for engraftment and survival

Leandro Martinez, Biljana Kraljacic, Kata Alilovic, Winnie Yip, Mayumi Sugita, Gail Roboz, Katherine Borden, Monica Guzman

Blood (2025) 146 (Supplement 1): 3248.

https://doi.org/10.1182/blood-2025-3248

Published: 2025

Journal Articles

Characterization of antecedent clonal hematopoiesis (CH) mutations in lymphoid and plasma cell neoplasms

Pinkal Desai, Zichan Li, Ying Li, Nuria Mencia-Trinchant, Kathryn Gorski, Wodan Ling, Ellen Ritchie, Michael Samuel, Jonathan Canaani, Michal Bar-Natan, Olivier Elemento, Lesley Tinker, Wendy Cozen, Monica Guzman, Andrea Sboner, Gail Roboz

Blood (2025) 146 (Supplement 1): 1399.

https://doi.org/10.1182/blood-2025-1399

Published: 2025

Journal Articles

Efficacy and safety of pivekimab sunirine in combination with venetoclax plus azacitidine in unfit patients with newly diagnosed Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 651.

https://doi.org/10.1182/blood-2025-651

Published: 2025

Journal Articles

A compelling case for central pathology review of multiparameter flow cytometry measurable residual disease results in Acute Myeloid Leukemia (AML) clinical trials: Data from the PALG-AML1/2016 multicenter randomized study

Blood (2025) 146 (Supplement 1): 1737.

https://doi.org/10.1182/blood-2025-1737

Published: 2025

Journal Articles

Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database

Jan Philipp Bewersdorf, Tariq Kewan, Luca Lanino, Wei Wei, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Hayley Hawkins, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Benjamin Rolles, Eunice Wang, Amyah Harris, Maria Amaya, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Jaclynn Campos, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop Enjeti, Kamal Alrabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Max Stahl, Matteo Della Porta, Rami Komrokji, Amer Zeidan

Blood (2025) 146 (Supplement 1): 606.

https://doi.org/10.1182/blood-2025-606

Published: 2025

Journal Articles

Analysis of hematologic improvement (HI) by time to response in Relapsed/Refractory Acute Myeloid Leukemia (AML) patients treated with olutasidenib

Shira Dinner, Brian Jonas, Antonio Curti, Stephane De Botton, Pau Montesinos, Karen W.L. Yee, Gail Roboz, William Blum, Gary Schiller, Jorge Cortes, Justin Watts, Andrew Wei, Aaron Sheppard, Hua Tian, Eunice Wang

Blood (2025) 146 (Supplement 1): 3439.

https://doi.org/10.1182/blood-2025-3439

Published: 2025

Journal Articles

Camelot-2: A phase 3 randomized, double-blind, placebo-controlled, study of bleximenib, venetoclax and azacitidine for the treatment of participants with newly diagnosed Acute Myeloid Leukemia harboring KMT2A rearrangements or NPM1 mutations, who are ineligible for intensive chemotherapy

Blood (2025) 146 (Supplement 1): 3429.

https://doi.org/10.1182/blood-2025-3429

Published: 2025

Journal Articles

Transfusion burden during the initial induction Phase in Acute Myeloid Leukemia is tightly associated with treatment intensity

Jonathan Canaani, Sarra Yekta, John-William Sidhom, Justin Kaner, Ellen Ritchie, Michal Bar-Natan, Michael Samuel, Pinkal Desai, Gail Roboz

Blood (2025) 146 (Supplement 1): 5172.

https://doi.org/10.1182/blood-2025-5172

Published: 2025

Journal Articles

Prospective assessment of measurable residual disease kinetics in intensively treated patients with Acute Myeloid Leukemia (AML) - results of the PALG-AML1/2016 study

Blood (2025) 146 (Supplement 1): 344.

https://doi.org/10.1182/blood-2025-344

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

Establishing contemporary benchmarks for Acute Myeloid Leukemia outcomes and measurable residual disease: Real-world data utilization from the ELN-david MRD international working group

Disease characteristics and outcomes of acute lymphoblastic leukemia (ALL) in adults with central nervous system (CNS) involvement

Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacitidine (Pbo+Aza) in patients with treatment-naïve, intermediate and higher-risk Myelodysplastic Syndromes (HR MDS)

Pharmacokinetics and cardiac impact of arsenic trioxide (ATO) oral solution (SDK001) under fasting, fed, and calcium carbonate co-administration conditions compared with intravenous ATO in patients with acute promyelocytic leukemia

A randomized, multicenter trial of shorter durations of hypomethylating agents in lower-risk Myelodysplastic Syndromes

Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: Phase 1b results from KOMET-007

Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007

ONC001: A first-in-class ADC targeting CD64 for the treatment of monocytic leukemia developed through patient-guided target and payload selection

Redefining eIF4E's function in Acute Myeloid Leukemia: Implications for engraftment and survival

Characterization of antecedent clonal hematopoiesis (CH) mutations in lymphoid and plasma cell neoplasms

Efficacy and safety of pivekimab sunirine in combination with venetoclax plus azacitidine in unfit patients with newly diagnosed Acute Myeloid Leukemia

A compelling case for central pathology review of multiparameter flow cytometry measurable residual disease results in Acute Myeloid Leukemia (AML) clinical trials: Data from the PALG-AML1/2016 multicenter randomized study

Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database

Analysis of hematologic improvement (HI) by time to response in Relapsed/Refractory Acute Myeloid Leukemia (AML) patients treated with olutasidenib

Camelot-2: A phase 3 randomized, double-blind, placebo-controlled, study of bleximenib, venetoclax and azacitidine for the treatment of participants with newly diagnosed Acute Myeloid Leukemia harboring KMT2A rearrangements or NPM1 mutations, who are ineligible for intensive chemotherapy

Transfusion burden during the initial induction Phase in Acute Myeloid Leukemia is tightly associated with treatment intensity

Prospective assessment of measurable residual disease kinetics in intensively treated patients with Acute Myeloid Leukemia (AML) - results of the PALG-AML1/2016 study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only